The world's only twice-a-year shot to prevent HIV could stop transmission -- if people can get it

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking studies, Gilead Sciences’ shot, a drug named lenacapavir, nearly eliminated new infections in two groundbreaking studies of people at high risk. It will be sold under the brand name Yeztugo. Wednesday’s approval marks the first step in an anticipated global rollout that experts say could protect millions — if they can get access. Drastic cuts to public health in the U.S. and abroad cloud the prospects.